The monitoring and assessment of the symptoms/features of Parkinson’s is a big deal in the research community at the moment.
There is currently a mad hunt for ‘biomarkers’ – reliably measurable physical characteristics – that could help not only with the assessment of individuals living with the condition, but could also aid in the running of clinical trials by providing additional measures of efficacy/benefit.
Recently an interesting perspective was written by some of the leading researchers in this field.
In today’s post, we review what the perspective outlined, and we will discuss other aspects of the biomarker research that need to be considered by the wider Parkinson’s community.
Perspective. Source: Huffingtonpost
Scientific journals will often invite the research leaders in a particular field of investigation to write a brief journal article that deals with unique view of a common problem.
Articles of this nature are called ‘Perspectives‘.
And recently a very interesting perspective was published in the journal Science on the topic of biomarkers for Parkinson’s.
Title: Finding useful biomarkers for Parkinson’s disease
Authors: Chen-Plotkin AS, Albin R,….a lot of additional authors…, Zhang J
Journal: Science Translational Medicine, 15 Aug 2018, 10 (454), eaam6003.
This perspective included a rather long list of a ‘who’s-who’ of Parkinson’s researchers – both academic and industry. Even members of the Michael J Fox Foundation and Verily/Google Life Sciences were included.
The perspective sought to highlight ‘the “ecosystem” of shared biofluid sample biorepositories and data sets will focus biomarker efforts in Parkinson’s‘. It is a very enlightening read, one that begs for reader responses. But sadly the article is behind a ‘pay wall’, and so many in the Parkinson’s community won’t be able to provide any thoughts or feedback.
But not to worry, we can discuss the matter here. And the best place to start that discussion is with the obvious first question:
What is a biomarker?
A biomarker is an objectively measurable physical characteristic associated with a condition. It is a biological component of a condition that correlates with that condition in some way. For example, the DaTscan brain imaging technique provides a ‘biomarker’ for Parkinson’s by measuring the amount of dopamine re-absorption in the brain. By labelling the dopamine neurons with a radioactive marker, we can quantify the levels of dopamine activity in a person.
An example of a DaTscan. Source: Cedars-sinai
What did the perspective say about biomarkers for Parkinson’s?
Today’s post involves massive multidimensional datasets, machine learning, and being able to predict the future.
Researchers are the National Institute on Aging and the University of Illinois at Urbana–Champaign have analysed longitudinal clinical data from the Parkinson’s Progression Marker Initiative (PPMI) and they have found three distinct disease subtypes with highly predictable progression rates.
NOTE: Reading about disease progression may be distressing for some readers, but please understand that this type of research is critical to helping us better understand Parkinson’s.
In today’s post, we will look at what the researchers found and discuss what this result could mean for the Parkinson’s community.
Today I am going to break one of the unwritten rules of science communication (again) .
Until a research report has been through the peer-review process you probably should not be discussing the results in the public domain.
But in this particular case, the research is really interesting. And it has been made available on the OPEN ACCESS preprint depository website called BioRxiv.
So what does the new research investigate?